VIICTR
Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.
Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med. 2018 05; 10(5).
View in:
PubMed
subject areas
Acetanilides
Animals
Cell Cycle Proteins
Cell Line, Tumor
Drug Resistance, Neoplasm
Gene Expression Profiling
Heterocyclic Compounds, 3-Ring
Humans
MAP Kinase Kinase 1
MAP Kinase Signaling System
Melanoma
Mice, Inbred C57BL
Mice, Inbred NOD
Mice, Knockout
Mice, SCID
Nuclear Proteins
Protein Kinase Inhibitors
Proteins
Proteomics
Salvage Therapy
Skin Neoplasms
Transcription Factors
Xenograft Model Antitumor Assays
authors with profiles
GORDON B MILLS